Mullins R J
University of Canberra (Associate Professor), Canberra, University of Sydney (Senior Lecturer), Sydney, Australian National University (Clinical Senior Lecturer), Canberra, Australia.
Clin Exp Allergy. 2003 Aug;33(8):1033-40. doi: 10.1046/j.1365-2222.2003.01671.x.
There are few studies on the incidence or recurrence of anaphylaxis.
To examine the incidence of anaphylaxis and risk factors for recurrence.
A prospective study of 432 patients referred to a community-based specialist practice in the Australian Capital Territory with anaphylaxis, followed by a survey to obtain information on recurrence.
Of 432 patients (48% male, 73% atopic, mean 27.4 years, SD 19.5, median 26) with anaphylaxis, 260 patients were seen after their first episode; 172 experienced 584 previous reactions. fifty-four percent of index episodes were treated in hospital. Aetiology was identified in 91.6% patients: food (61%), stinging insects (20.4%) or medication (8.3%). The minimum occurrence and incidence of new cases of anaphylaxis was estimated at 12.6 and 9.9 episodes/100,000 patient-years, respectively. Follow-up data were obtained from 304 patients (674 patient-years). One hundred and thirty experienced further symptoms (45 serious), 35 required hospitalization and 19 administered adrenaline. Accidental ingestion of peanut/tree nut caused the largest number of relapses, but the highest risk of recurrence was associated with sensitivity to wheat and/or exercise. Rates of overall and serious recurrence were 57 and 10 episodes/100 patient-years, respectively. Of those prescribed adrenaline, 3/4 carried it, 2/3 were in date, and only 1/2 patients faced with serious symptoms administered adrenaline. Five patients each developed new triggers for anaphylaxis, or re-presented with significant psychiatric symptoms.
In any 1 year, 1/12 patients who have suffered anaphylaxis will experience recurrence, and 1/50 will require hospital treatment or use adrenaline. Compliance with carrying and using adrenaline is poor. Occasional patients develop new triggers or suffer psychiatric morbidity.
关于过敏反应的发病率或复发情况的研究较少。
研究过敏反应的发病率及复发的危险因素。
对澳大利亚首都地区一家社区专科诊所接诊的432例过敏反应患者进行前瞻性研究,随后进行一项调查以获取复发信息。
432例过敏反应患者(男性占48%,特应性体质者占73%,平均年龄27.4岁,标准差19.5,中位数26岁)中,260例在首次发作后前来就诊;172例有过584次既往反应。54%的首次发作在医院接受治疗。91.6%的患者明确了病因:食物(61%)、蜇人昆虫(20.4%)或药物(8.3%)。过敏反应新病例的最低发生数和发病率分别估计为12.6例和9.9例/100,000患者年。从304例患者(674患者年)获得了随访数据。130例出现了进一步症状(45例严重),35例需要住院治疗,19例使用了肾上腺素。意外摄入花生/坚果导致复发的次数最多,但复发风险最高的是对小麦和/或运动敏感。总体复发率和严重复发率分别为57例和10例/100患者年。在开具肾上腺素处方的患者中,四分之三随身携带,三分之二在有效期内,只有二分之一面临严重症状的患者使用了肾上腺素。5例患者分别出现了新的过敏反应触发因素,或再次出现明显的精神症状。
在任何1年中,1/12的过敏反应患者会复发,1/50的患者需要住院治疗或使用肾上腺素。随身携带和使用肾上腺素的依从性较差。少数患者出现新的触发因素或患有精神疾病。